Skip to main content
. 2024 Jan 19;10(1):e003837. doi: 10.1136/rmdopen-2023-003837

Figure 1.

Figure 1

The improvement in cutaneous disease activity in a dermatomyositis patient who transitioned to upadacitinib after failing tofacitinib, including photos at assessment pre tofacitinib (A), post tofacitinib (B) and post upadacitinib (C).